Pain Management During Diagnostic Office Hysteroscopy in Postmenopausal Women: a Randomized Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Lidocaine-Prilocaine Topical, Saline spray.
- Who it may be relevant to
- Registry conditions: Office Hysteroscopy. Basic parameters: No limits · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Pain Management With Lidocaine-prilocaine Spray During Diagnostic Office Hysteroscopy in Postmenopausal Women: a Randomized Controlled Study
Overview
To assess the effectiveness of lidocaine-prilocaine spray versus placebo in minimizing the pain experienced by postmenopausal patients during diagnostic office hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopists
Detailed description
To assess the effectiveness of lidocaine-prilocaine spray versus placebo in minimizing the pain experienced by postmenopausal patients during diagnostic office hysteroscopy and to assess the ease of insertion of hysteroscope as reported by the hysteroscopists
Interventions
- Drug Lidocaine-Prilocaine Topical
lidocaine-prilocaine spray on the cervix and cervical canal 5-7 minutes prior to the procedure - Drug Saline spray
saline spray on the cervix and cervical canal 5-7 minutes prior to the procedure
Primary outcome measures
- Intensity of pain [Time frame: 5 minutes]
Secondary outcome measures (2)
- Intensity of pain [Time frame: 20 minutes]
- ease of insertion [Time frame: 5 MINUTES]
Eligibility criteria
Inclusion criteria
- Menopausal patients with an indication for office hysteroscopy (postmenopausal bleeding or abnormal ultrasound findings)
Exclusion criteria
- Nulliparous patients patients with cervical pathology retroverted uterus (detected by transvaginal ultrasound) previous cervical surgery patients with severe vaginal bleeding allergy or contraindications to lidocaine-prilocaine spray
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06767085 · LP SPRAY HYSTEROSCOPY